EP 2102209 A2 20090923 - NOVEL TRIAZABENZO[A]NAPHTHO[2,1,8-cde]AZULENE DERIVATIVES, METHOD FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
Title (en)
NOVEL TRIAZABENZO[A]NAPHTHO[2,1,8-cde]AZULENE DERIVATIVES, METHOD FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
Title (de)
NEUARTIGE TRIAZABENZO-[A]-NAPHTHO-[2,1,8-cde]-AZULEN-DERIVATE, VERFAHREN ZU IHRER HERSTELLUNG UND PHARMAZEUTISCHE ZUSAMMENSETZUNGEN DAMIT
Title (fr)
NOUVEAUX DÉRIVÉS TRIAZABENZO[A]NAPHTHO[2,1,8-cde]AZULÈNE, LEUR PROCÉDÉ DE PRÉPARATION ET LES COMPOSITIONS PHARMACEUTIQUES QUI LES CONTIENNENT
Publication
Application
Priority
- FR 2008000012 W 20080104
- FR 0700046 A 20070105
Abstract (en)
[origin: FR2911141A1] Triazabenzo[a]naphtho[2,1,8-cde]azulene derivatives (I) are new. Triazabenzo[a]naphtho[2,1,8-cde]azulene derivatives of formula (I) are new. R 1H, 1-6C alkyl, 1-6C aminoalkyl or 1-6C hydroxyalkyl; R 2H; R 1+R 2 = a bond; R 3H; R 4H, Me, 3-6C alkyl, 1-6C aminoalkyl, 1-6C hydroxyalkyl, aryl(1-6C)alkyl or heterocycloalkyl(1-6C)alkyl; R 3+R 4a bond; R 5-R 8H, or R 5+R 6 and/or R 7+R 8 = O, S or NH; R 9H, halo, 1-6C alkyl (optionally substituted with Q), 1-6C alkoxy, OH, CN, NO 2, 1-6C polyhaloalkyl or NRR"; R, R" : H, 1-6C alkyl or 2-6C alkenyl; R 10, R 11H, halo, 1-6C alkyl, 1-6C alkoxy, OH, CN, NO 2, 1-6C polyhaloalkyl or NRR"; n : 0-4; m : 0-2; p : 0-3; X : NR 12; R 12H, 1-6C alkyl (optionally substituted with Q), 2-6C alkenyl (optionally substituted with Q), aryl(1-6C)alkyl, 1-6C polyhaloalkyl; aryl : optionally substituted phenyl or naphthyl; Q : halo, OH, 1-6C alkyl, 1-6C alkoxy, NH 2 or mono- or di(1-6C alkyl)amino. An independent claim is also included for a process for preparing (I). [Image] ACTIVITY : Antidepressant; Tranquilizer; Nootropic; Neuroprotective; Antiparkinsonian. MECHANISM OF ACTION : Tyrosine hydroxylase inducer. Administering (5aRS,12aSR,12bSR,12cSR)-7-chloro-2,3,5a,10,12a,12b,12c-hexahydro-1H,4H-3a,9b,11-triazabenzo[a]naphtho[2,1,8-cde]azulene-10,12(5H,11H)-dione to mice by intraperitoneal injection (20 mg/kg) gave a 53% increase in tyrosine hydroxylase level in an anterior section of the locus coeruleus.
IPC 8 full level
A61K 31/551 (2006.01); A61P 25/00 (2006.01); C07D 471/22 (2006.01)
CPC (source: EP KR US)
A61K 31/551 (2013.01 - KR); A61P 25/00 (2017.12 - EP); A61P 25/16 (2017.12 - EP); A61P 25/18 (2017.12 - EP); A61P 25/22 (2017.12 - EP); A61P 25/24 (2017.12 - EP); A61P 25/28 (2017.12 - EP); A61P 43/00 (2017.12 - EP); C07D 471/22 (2013.01 - EP KR US)
Citation (search report)
See references of WO 2008099081A2
Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR
Designated extension state (EPC)
AL BA MK RS
DOCDB simple family (publication)
FR 2911141 A1 20080711; FR 2911141 B1 20090220; AR 064747 A1 20090422; AU 2008214548 A1 20080821; BR PI0806290 A2 20110906; CA 2674083 A1 20080821; CN 101611034 A 20091223; EA 200900922 A1 20100226; EP 2102209 A2 20090923; JP 2010514825 A 20100506; KR 20090096749 A 20090914; MA 31144 B1 20100201; MX 2009007199 A 20090812; US 2010105666 A1 20100429; WO 2008099081 A2 20080821; WO 2008099081 A3 20081023
DOCDB simple family (application)
FR 0700046 A 20070105; AR P080100029 A 20080104; AU 2008214548 A 20080104; BR PI0806290 A 20080104; CA 2674083 A 20080104; CN 200880001777 A 20080104; EA 200900922 A 20080104; EP 08761736 A 20080104; FR 2008000012 W 20080104; JP 2009544432 A 20080104; KR 20097016386 A 20080104; MA 32051 A 20090629; MX 2009007199 A 20080104; US 44862708 A 20080104